New investors, HealthCap and Hadean Growth Fund, joined the round, led by Innovestor Life Science.

”HealthCap’s participation is a tremendous addition to our Series B round. Their solid experience in the life science sector significantly enhances our syndicate, providing robust support for our ambitious goals,” says Pekka Simula, Partner at Innovestor Life Science.

These additional funds will facilitate the preparation of the future Phase 3 program of vipoglanstat, a drug candidate aimed at revolutionizing the treatment of endometriosis.

In conjunction with this capital infusion, Gesynta Pharma strengthens its board with the appointment of three new directors: Kristina Ekberg, partner at HealthCap, and independent directors Cristina Csimma and David Colpman.

Phase 2 clinical trial for vipoglanstat

Gesynta Pharma is preparing a Phase 2 clinical trial for vipoglanstat, a novel non hormonal, nonopioid treatment for endometriosis. The upcoming clinical proof-of-concept study will include approximately 190 patients in several countries across Europe, describes the company.

“It is with great enthusiasm that we join this robust investor syndicate, dedicated to addressing a significant unmet medical need,” says HealthCap partner Kristina Ekberg. “This investment reflects our strong confidence in Gesynta Pharma’s vision and its potential to deliver a genuine breakthrough in women’s health.”